MELBOURNE, Australia and SAN DIEGO, May 22, 2017 /PRNewswire/ — Invetech, a leader in instrument development, custom automation, and contract manufacturing, has announced refinements to its senior management structure as it continues to pursue growth in the Diagnostics, Connected Health and Cell Therapy automation markets.
Anthony Annibale has accepted the role of Global VP Sales, Diagnostics and Healthcare
Anthony is a proven product development leader with more than 20 years of experience in markets including medical devices, pharmaceuticals, biotech and consumer products. As global VP sales, diagnostics and connected health, Anthony is responsible for leading the expansion of our North American and European Markets, where his skills and leadership in human-centered design and connectivity are vital in the rapidly evolving diagnostics and broader healthcare markets. In his most recent role at Invetech, Anthony was responsible for leading Invetech’s consumer technology and medical device groups. Anthony holds a bachelor’s degree in Mechanical Engineering from Old Dominion University.
Vijay Kathir has accepted a newly created role of VP, Finance
Vijay joins Invetech with 30 years of experience in corporate finance for companies based in the United States, Canada, the United Kingdom and Australia. Most recently, Vijay has worked with Danaher dental technologies company Sybron, and Gilbarco Veeder-Root, a global leader in fuel dispenser technology and member of the Fortive group. Vijay holds a bachelor’s degree in Accounting from Hatfield Polytechnic in the U.K. and is recognized as a Chartered Accountant in England, Wales and Australia.
“These two appointments position Invetech to meet the changing needs of our clients and the market,” said Andreas Knaack, president of Invetech. “Anthony’s market knowledge and understanding of trends in connected health will help our clients realize new technologies and grow their market offerings. Similarly, Vijay brings a unique combination of financial expertise, operational acumen and technology industry knowledge that will be a key asset as we focus on business expansion.”
Invetech has created breakthrough products and custom automation systems for more than 30 years. With experience drawn from more than 5,000 projects globally, Invetech partners with global leaders in industry to deliver product design and development, contract manufacturing and custom automation services. The company has experience in a broad range of market sectors including laboratory diagnostics, point of care diagnostics, life sciences, and cell and advanced therapy automated production systems. To learn more about Invetech, please contact us at www.invetech.us.
Thermo Fisher Scientific Introduces Latest in Capillary Electrophoresis Technology with new Applied Biosystems(TM) SeqStudio(TM) Genetic Analyzer
New low-throughput Sanger sequencing and fragment analysis platform offers trusted technology and workflow with all-in-one cartridge system and cloud connectivity
SOUTH SAN FRANCISCO, Calif., May 22, 2017 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, launched today a new capillary electrophoresis (CE) system designed to offer a low-throughput, cartridge-based system for Sanger sequencing and fragment analysis. For use with oncology research, genome editing, species identification, and human cell line authentication among other common applications, the Applied Biosystems™ SeqStudio™ Genetic Analyzer supports the growing need for an affordable and easy-to-use CE platform. The SeqStudio Genetic Analyzer will be displayed publically for the first time in the Thermo Fisher Scientific booth (#438) at the annual European Society of Human Genetics (ESHG) Conference in Copenhagen, Denmark, May 27-30, 2017.
The new SeqStudio Genetic Analyzer utilizes a unique all-in-one cartridge that combines the capillary array, polymer reservoir and anode buffer, which vastly simplifies preparation and hands-on processing time. Other innovative features of the system allow customers to access individualized protocols, an intuitive touchscreen and connectivity to the Thermo Fisher Cloud for remote setup and monitoring as well as easy data analysis and collaboration.
“Sanger sequencing using CE, which is celebrating its 40th anniversary this year, is the gold standard sequencing technology. It helped discover novel biological findings such as the first breast cancer gene (BRCA1) and was used to complete the Human Genome Project in 2003,” said Kim Kelderman, vice president and general manager of Genetic Analysis at Thermo Fisher Scientific. “The SeqStudio Genetic Analyzer is a smart and state-of-the-art system that provides researchers with a truly plug and play system.”
The SeqStudio instrument has a small footprint, with an onboard computer and integrated touchscreen that makes run setup quick, intuitive and flexible. The system allows sequencing and fragment analysis runs on the same plate without the need to change any consumables. This opens new opportunities for streamlining analyses – for example, combining a locus screening test with a copy number variability test on the same CE plate.
The SeqStudio Genetic Analyzer will be available to all global markets in the second half of 2017 and is already in use by select customers in North America, EMEA, Japan and China. These early-access customers have reported exciting successes with more than 2,000 combined runs on the system.
“I am very enthusiastic about the launch of this new CE system because it brings down the cost of capillary electrophoresis platforms and is very simple to operate,” said Jan Schouten, CEO of MRC Holland, which is a SeqStudio early access site that develops MLPA-based fragment analysis assays for the detection of small copy number changes. “The system can handle a complete microtiter sample plate and has sufficient capacity for both low- and mid-throughput genetic laboratories.”
For more information about the SeqStudio Genetic Analyzer or to learn more about Thermo Fisher’s Sanger sequencing applications, please visit www.thermofisher.com/seqstudio. To watch an overview video of the SeqStudio, click here. Thermo Fisher will also host a live unveiling of the SeqStudio Genetic Analyzer via a video broadcast beginning at 7 a.m. PT today. To view the presentation live or on demand later, click here.
SeqStudio Genetic Analyzer is for Research Use Only; not intended for diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Media Contact Information:
Thermo Fisher Scientific
+1 760 929 2456
+1 908 208 9254
SOURCE Thermo Fisher Scientific Inc.
SAN DIEGO, May 22, 2017 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the closing of its public offering of common stock and Series G Preferred Stock for a total of $4.1 million. Sold in the offering was a combination of common stock and Series G Preferred Stock at $1.75 per share of common stock and Series G Preferred Stock. The gross proceeds of the public offering were $4.1 million before the underwriter’s discount and expenses. Both OPKO Health, Inc. (NYSE: OPK) and Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc. participated in the offering. The Series G Preferred Stock will not be separately listed on any securities exchange or other trading market.
Laidlaw & Company (UK) Ltd. acted as the sole underwriter for this offering.
A registration statement relating to these securities was previously filed on Form S-1 (333-216016) with the Securities and Exchange Commission (the “SEC”), and was declared effective by the SEC on May 12, 2017. A final prospectus relating to the offering may be obtained on the SEC’s website located at www.sec.gov, and electronic copies of the final prospectus may also be obtained from Laidlaw & Company (UK) Ltd., Attention: Syndicate Department, 546 Fifth Avenue, New York, NY 10036, by telephone at (212) 953-4900 or by email at email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our lead antibody is directed at an antigen target expressed on more than 90% of pancreatic cancers and a significant amount of other GI and lung cancers, making the antibody potentially broadly applicable to a wide variety of patients suffering from difficult to treat cancers. With our collaborators including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging Endpoints, we have treated over 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase I clinical studies, and demonstrated early safety, specificity for the target and an early efficacy signal. Results of these trials should be published by mid-year 2017. Additionally, our Phase I clinical study of our radioimmunotherapy product designated as MVT-1075 has been authorized to proceed by the FDA and will soon commence with patient enrollment. For additional information, please visit the Company’s website, www.mabvax.com.
Forward Looking Statements:
This press release on announcing the closing of our public offering contains “forward-looking statements” regarding matters that are not historical facts, including statements relating to the Company’s clinical trials and product development pipeline. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
SOURCE MabVax Therapeutics Holdings, Inc.
NuVasive Announces Educational Initiatives In Support Of Spine’s Fastest Growing Spinal Deformity Portfolio
SAN DIEGO, May 22, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company’s increased investment and support of adult and pediatric deformity research, education, and awareness initiatives throughout 2017.
NuVasive increased its focus on the $2.5 billion deformity market in May 2015 with the launch of its Integrated Global Alignment® (iGA®) platform and RELINE® posterior fixation system. In February 2016, NuVasive expanded its footprint into the early onset scoliosis market with the addition of its industry-leading MAGEC® system, which utilizes innovative magnetic technology within adjustable growing rods. Today, NuVasive has the fastest growing spinal deformity portfolio and is expanding its support of key programs to drive improved clinical and economic outcomes. NuVasive recently launched the ‘Embracing the Journey Together‘ program, which includes pediatric spinal deformity research, education and spinal deformity event support, supporting leading surgeons as they educate surgeons around the world.
“At NuVasive, we remain laser-focused on transforming the lives of patients through disruptive innovation and support of clinical education and research,” said Greg Lucier, NuVasive chairman and chief executive officer. “We’ve made tremendous gains in adult and pediatric spinal deformity innovation, with the versatile RELINE portfolio and MAGEC system. With the upcoming launch of the RELINE Small Stature system available this summer, I’m confident in our ability to outpace the market. We’re proud NuVasive has taken the lead in supporting key global initiatives designed to help improve the lives of patients around the world.”
Part of the Company’s investment into pediatric spinal deformity care includes funding research and patient initiatives, such as the Harms Study Group and its Setting Scoliosis Straight Foundation, as the exclusive sponsor of the Power Over Scoliosis event. NuVasive is also providing research funding for the Children’s Spine Study Group and the Growing Spine Study Group.
NuVasive was a key sponsor of EPOSNA 2017, the combined meeting of EPOS and POSNA, held earlier this month in Barcelona, Spain. In July, NuVasive is the leading sponsor of IMAST 2017, the International Meeting on Advanced Spine Techniques hosted by the Scoliosis Research Society. The Company is also the leading sponsor of ICEOS, the International Congress of Early-onset Scoliosis, in November.
The Company also announced the launch of a monthly podcast series, MAGEC Matters, featuring interviews with leading surgeons in pediatric deformity discussing tips for the treatment of early onset scoliosis, which is now available on iTunes, SoundCloud and other leading podcast platforms.
Other events supported by NuVasive throughout 2017 include:
- Setting Scoliosis Straight: Patient & Family Power over Scoliosis Educational Event
June 2-3, 2017; Miami
- Shriners Hospital for Children – Chicago “Early Onset Scoliosis and Management Strategies” Meeting
June 9, 2017; Chicago
- International Meeting on Advanced Spine Techniques (IMAST)
July 12-15, 2017; Cape Town, South Africa
- Scoliosis Research Society (SRS)
Sept. 6-9, 2017; Philadelphia
- Pediatric Orthopedic Surgical Techniques Lab (POST)
Sept. 29-30, 2017; Memphis, Tenn.
- International Congress of Early-onset Scoliosis (ICEOS)
Nov. 16-17; 2017, San Diego
- 2017 MAGEC Users Meeting
Nov. 17-18, 2017; San Diego
- International Pediatric Orthopaedic Symposium (IPOS)
Nov. 28-Dec 2, 2017; Orlando, Fla.
- Spina Bifida Association Walk-n-Roll Events
Various U.S. cities throughout 2017
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA®platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
Assists with the development of project plans, monitors for accomplishment, closes projects, and provides summaries/feedback for proposed process changes….From Sorrento Therapeutics – Mon, 22 May 2017 08:57:44 GMT – View all San Diego, CA jobs
Is an innovative biotechnology company located in the Los Angeles area (near Pasadena) and in San Diego. We have a very deep drug development pipeline including…From BioSpace.com – Mon, 22 May 2017 07:57:47 GMT – View all San Diego, CA jobs
We are currently looking for an In Vivo RA to work for a leading San Diego biotechnology company. BioPhase Solutions specializes in recruiting top talented…From BioPhase Solutions – Mon, 22 May 2017 05:03:32 GMT – View all San Diego, CA jobs
We are currently looking for a Manufacturing Associate, Cell Culture to work for a leading San Diego biotechnology company….From BioPhase Solutions – Mon, 22 May 2017 05:03:31 GMT – View all San Diego, CA jobs
30% to 50% travel, to visit pharmaceutical, biotechnology’ and consumer company prospects and attend meetings. _As this is a small and innovative company who is… $120,000 – $145,000 a year
From Indeed – Sun, 21 May 2017 08:40:52 GMT – View all San Diego, CA jobs
Create detailed implementation plans based on Core Informatics Customer Implementation Methodology. Experience within the biotech or pharmaceutical industry is…From Core Informatics – Sun, 21 May 2017 05:55:25 GMT – View all San Diego, CA jobs